This site is intended for healthcare professionals

Four-year Biktarvy data presented at IAS 2021

Read time: 2 mins
Last updated:28th Jul 2021
Published:19th Jul 2021
Gilead Sciences, Inc. announced a pooled analysis of a 48-week open-label extension of two Phase III studies (Study 1489 and Study 1490) shows 99% of participants who initiated treatment with Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) maintained an undetectable viral load (HIV-1 RNA <50 copies ml) through four years of follow-up (week 192, n="476/480," missing="excluded)." in the 48-week open-label extension, there were zero cases of treatment-emergent resistance to any components of biktarvy in participants treated with biktarvy. these findings, along with long-term data from phase iii studies in virologically suppressed black americans and virologically suppressed people living with hiv aged 65 and older, demonstrated biktarvy sustains efficacy with a high barrier to resistance across a range of people living with hiv, inclusive of their treatment history, gender, race or age. these data were presented at the 11th international aids society (ias) conference on hiv science.></50>
Condition: HIV/AIDS
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest